Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04604496 · ClinicalTrials.gov registry record · Phase 1
Study OF PF-06882961 IN Participants With AND Without Varying Degrees OF Hepatic Impairement
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04604496 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT04604496, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961
Interventions
- DRUG PF-06882961 20MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-12-30 |
| Est. Completion | 2022-01-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04604496
The ClinicalTrials.gov registry entry for NCT04604496 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06882961 20MG is the first listed.
NCT04604496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04604496 about?
NCT04604496 is a clinical study titled "Study OF PF-06882961 IN Participants With AND Without Varying Degrees OF Hepatic Impairement". The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma Pharmacokinetic (PK) of PF-06882961
What is the current status of trial NCT04604496?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-12-30. Estimated completion is 2022-01-10.
What interventions are being tested in trial NCT04604496?
The interventions under investigation include: PF-06882961 20MG (DRUG).
Who is sponsoring clinical trial NCT04604496?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.